What is Adult-onset Still disease?
Adult-onset Still disease (AOSD) is a rare autoinflammatory condition characterized by high spiking fevers, a distinctive salmon-colored rash, and joint pain. This systemic inflammatory disorder affects adults, typically between ages 16-35 and 36-46, with no clear genetic inheritance pattern. AOSD occurs in approximately 0.16-0.4 per 100,000 people worldwide, making it an exceptionally rare condition that often presents diagnostic challenges for both patients and healthcare providers.
Key statistics
| Prevalence: | 0.16-0.4 per 100,000 people |
| Peak onset ages: | 16-35 years and 36-46 years (bimodal distribution) |
| Gender ratio: | Slightly more common in women (1.5:1) |
| Inheritance: | Not inherited; sporadic occurrence |
Symptoms
High fever, salmon-colored rash, joint pain, muscle pain, sore throat, swollen lymph nodes, enlarged spleen, weight loss, fatigue.
The hallmark symptoms of AOSD typically appear suddenly and can be severe. The most characteristic feature is daily high-spiking fever, often reaching 39°C (102°F) or higher, usually occurring in late afternoon or evening and returning to normal or below normal in the morning. During fever spikes, patients develop a distinctive salmon-pink, non-itchy rash that appears on the trunk and extremities, often described as evanescent because it comes and goes with the fever.
Joint symptoms include severe pain and stiffness, particularly affecting the wrists, knees, and ankles. Unlike rheumatoid arthritis, the joint inflammation in AOSD may not cause permanent damage initially, though chronic arthritis can develop over time. Many patients experience significant muscle pain and a persistent, severe sore throat that doesn’t respond to antibiotics.
Systemic symptoms include profound fatigue, unintentional weight loss, swollen lymph nodes, and an enlarged spleen (splenomegaly). Some patients develop pleuritis (lung lining inflammation) or pericarditis (heart lining inflammation), which can cause chest pain and breathing difficulties.
Causes and risk factors
AOSD is classified as an autoinflammatory disorder, meaning the body’s innate immune system becomes overactive without a clear trigger. Unlike autoimmune diseases where the adaptive immune system mistakenly attacks healthy tissue, autoinflammatory conditions involve dysregulation of the inflammatory response itself.
The exact cause remains unknown, but research suggests a combination of genetic susceptibility and environmental triggers. Some studies indicate associations with certain HLA (human leukocyte antigen) types, particularly HLA-B17, HLA-B18, HLA-B35, and HLA-DR4, though no single genetic mutation has been identified.
Environmental triggers may include viral or bacterial infections, with some cases appearing after upper respiratory infections, though no specific infectious agent has been definitively linked to AOSD. Stress, both physical and emotional, may also play a role in triggering the condition in susceptible individuals.
Prevention
Currently, there are no evidence-based prevention strategies for AOSD because it is not an inherited genetic condition and its triggers remain largely unknown. Since AOSD appears to be sporadic with no clear familial clustering, genetic testing and carrier screening are not applicable.
However, maintaining overall immune system health through regular exercise, adequate sleep, stress management, and avoiding unnecessary immunosuppression may be beneficial for general health. Prompt treatment of infections and avoiding known inflammatory triggers, once identified in individual patients, may help prevent flares in those already diagnosed.
Complications
Without proper treatment, AOSD can lead to serious complications affecting multiple organ systems. Chronic arthritis may develop, potentially causing joint damage and disability, particularly in the wrists and cervical spine. Some patients develop destructive arthritis resembling rheumatoid arthritis.
Macrophage activation syndrome (MAS) is a life-threatening complication occurring in approximately 10-15% of AOSD patients. MAS involves excessive activation of immune cells called macrophages, leading to cytokine storm, organ dysfunction, and potentially fatal outcomes if not promptly recognized and treated.
Other serious complications include liver dysfunction with elevated liver enzymes, heart complications such as pericarditis or myocarditis, lung involvement including pleural effusions or pulmonary fibrosis, and kidney problems. Chronic inflammation can also lead to secondary amyloidosis, a condition where abnormal proteins deposit in organs, potentially causing organ failure.
The persistent inflammation and pain can significantly impact mental health, leading to depression and anxiety disorders that require appropriate psychological support and treatment.
Diagnosis
Diagnosing AOSD is challenging because there are no specific diagnostic tests, and the condition must be differentiated from infections, malignancies, and other inflammatory diseases. Physicians typically use the Yamaguchi criteria, which require the presence of major and minor criteria along with exclusion of other conditions.
Major criteria include fever of 39°C or higher for at least one week, arthralgia for two weeks or longer, typical salmon-colored rash, and white blood cell count of 10,000 or higher with neutrophil predominance. Minor criteria include sore throat, lymph node enlargement, enlarged spleen or liver, abnormal liver function tests, and negative rheumatoid factor and antinuclear antibodies.
Laboratory findings characteristically show extremely elevated ferritin levels, often exceeding 1,000 ng/mL and sometimes reaching over 10,000 ng/mL. Elevated inflammatory markers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are typical. A glycosylated ferritin percentage below 20% can help distinguish AOSD from other conditions causing high ferritin.
Additional tests may include bone marrow biopsy to exclude malignancy, imaging studies such as chest X-rays or CT scans to assess organ involvement, and tissue biopsies if organ-specific symptoms are present. Genetic testing is not routinely performed as no specific genetic mutations are associated with AOSD.
Treatment
Treatment of AOSD focuses on controlling inflammation and preventing organ damage. The approach is typically escalated based on disease severity and response to initial therapies.
First-line treatment often includes high-dose corticosteroids such as prednisolone or methylprednisolone, which can rapidly control acute symptoms but are not suitable for long-term use due to significant side effects. Nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin may provide symptomatic relief for mild cases.
For patients requiring steroid-sparing therapy or those with refractory disease, several targeted biologics have shown effectiveness. Anakinra, an interleukin-1 receptor antagonist, is often considered first-line biologic therapy and can be particularly effective for the systemic features of AOSD. Canakinumab, another IL-1 inhibitor, has shown promise in clinical studies and may be used for patients who don’t respond to anakinra.
Tocilizumab, an interleukin-6 receptor antagonist, has demonstrated efficacy in treating both systemic and arthritic manifestations of AOSD. Other treatment options may include conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, particularly for patients with predominant joint involvement.
For life-threatening complications like macrophage activation syndrome, intensive immunosuppressive therapy including high-dose corticosteroids, cyclosporine, or etoposide may be necessary.
Prognosis
The prognosis for AOSD varies significantly depending on the disease pattern and response to treatment. Three main disease courses have been identified: self-limiting (monophasic), intermittent (polyphasic), and chronic persistent patterns.
Approximately 30-40% of patients experience a self-limiting course with complete resolution after the initial episode, typically within several months to a year. About 30-35% have an intermittent pattern with recurrent flares separated by periods of remission. The remaining 25-40% develop chronic persistent disease with ongoing symptoms and potential for joint damage.
With appropriate treatment, most patients can achieve good symptom control and maintain reasonable quality of life. Early diagnosis and treatment with biologics have significantly improved outcomes, particularly in preventing joint destruction and managing systemic complications.
Long-term mortality is generally low, estimated at less than 10%, with deaths typically related to complications such as macrophage activation syndrome, liver failure, or secondary infections due to immunosuppressive therapy. Patients with chronic arthritis may develop functional disability, but this can often be minimized with proper treatment.
Quality of life
Living with AOSD requires significant lifestyle adjustments and ongoing medical management. During active disease phases, patients often experience severe fatigue that may limit work and social activities. Maintaining a regular sleep schedule and incorporating stress management techniques such as meditation or yoga can help manage symptoms.
Regular, moderate exercise is important for maintaining joint function and overall health, though activities may need to be modified during flares. Swimming and gentle stretching exercises are often well-tolerated. Physical therapy can help maintain joint mobility and muscle strength.
Dietary considerations may include maintaining adequate nutrition during periods of poor appetite and weight loss. Some patients find that certain foods trigger inflammation, though no specific AOSD diet has been proven effective. Adequate calcium and vitamin D supplementation is important for patients on long-term corticosteroids.
Mental health support is crucial, as chronic illness can lead to depression and anxiety. Connecting with support groups, either in-person or online, can provide valuable emotional support and practical advice from others with similar experiences.
Work accommodations may be necessary during flares, including flexible schedules, modified duties, or temporary disability leave. Many patients can maintain employment with appropriate treatment and workplace modifications.
Pregnancy and fertility
AOSD can affect women of childbearing age, making pregnancy planning important. The disease itself does not typically impair fertility, but some medications used for treatment may have fertility implications.
Pregnancy outcomes in women with AOSD are generally favorable, particularly when the disease is well-controlled before conception. However, disease activity may fluctuate during pregnancy, with some women experiencing improvement while others may have flares.
Medication safety during pregnancy requires careful consideration. Corticosteroids are generally considered safe when necessary, though high doses should be avoided when possible. Many conventional DMARDs like methotrexate must be discontinued before conception due to teratogenic effects. Some biologics may be continued during pregnancy under close medical supervision, though individual risk-benefit assessments are necessary.
Preconception counseling with rheumatologists and maternal-fetal medicine specialists is recommended to optimize disease control and medication regimens before pregnancy.
Children
While AOSD by definition occurs in adults, a similar condition called systemic juvenile idiopathic arthritis (sJIA) affects children and shares many clinical features with AOSD. Some experts consider these conditions part of the same disease spectrum.
Children who develop systemic inflammatory arthritis before age 16 are typically classified as having sJIA rather than AOSD, though the clinical manifestations, laboratory findings, and treatment approaches are quite similar.
Family members of AOSD patients do not have significantly increased risk of developing the condition, as it is not inherited in a Mendelian pattern.
When to see a doctor
Urgent medical attention is needed for sustained high fever (39°C/102°F or higher) lasting more than a few days, especially when accompanied by salmon-colored rash, severe joint pain, or systemic symptoms like significant weight loss or breathing difficulties.
Emergency care should be sought immediately for signs of macrophage activation syndrome, including rapidly worsening fever, confusion, bleeding or bruising, severe fatigue, or any signs of organ dysfunction.
Patients with diagnosed AOSD should contact their healthcare provider for persistent fever despite treatment, new or worsening joint symptoms, signs of infection (which may be masked by immunosuppressive medications), or any concerning side effects from medications.
Regular monitoring appointments are essential for patients on biologic therapies or other immunosuppressive treatments to assess treatment response and screen for potential complications.
Regional context
Limited data exists specifically for AOSD prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) or broader Eastern Mediterranean area. The condition appears to occur across all ethnic groups and geographic regions studied, though most published research comes from North America, Europe, and East Asia.
Given the rarity of AOSD and potential for underdiagnosis in regions with limited rheumatology resources, the Global Medical Journal welcomes contributions from healthcare providers in the Caucasus and Eastern Mediterranean regions who have experience with AOSD cases, as regional case series could provide valuable insights into local presentation patterns and treatment responses.
Research and clinical trials
Current research focuses on better understanding the underlying inflammatory mechanisms driving AOSD and developing more targeted therapies. Studies are investigating the role of various cytokines beyond IL-1 and IL-6, including tumor necrosis factor-alpha and interferons.
Recent breakthroughs include improved understanding of the innate immune system dysfunction in AOSD and the development of biomarkers for disease monitoring. Research into the glycosylated ferritin test has improved diagnostic accuracy and disease monitoring capabilities.
Several clinical trials are evaluating new biologic therapies and treatment protocols. Ongoing studies are examining optimal dosing strategies for existing biologics and investigating combination therapies for refractory cases.
Patients interested in clinical trials can search ClinicalTrials.gov using terms like “Adult-onset Still disease” or “AOSD” to find current studies. Participation in clinical trials can provide access to cutting-edge treatments while contributing to medical knowledge about this rare condition.
Frequently asked questions
Is Adult-onset Still disease contagious?
No, AOSD is not contagious. It is an autoinflammatory condition caused by immune system dysfunction, not an infection that can spread from person to person.
Will I need to take medication for life?
Not necessarily. Some patients with the self-limiting form of AOSD may not require long-term treatment after the initial episode resolves. However, those with chronic or intermittent patterns often benefit from ongoing therapy to prevent flares and joint damage.
Can AOSD cause permanent joint damage?
While early AOSD may not cause permanent joint damage, chronic arthritis can develop over time, particularly affecting the wrists and neck. Early aggressive treatment with appropriate medications can help prevent or minimize joint destruction.
Are there dietary changes that can help with AOSD?
No specific diet has been proven to treat AOSD, but maintaining good nutrition is important. Some patients notice certain foods trigger inflammation, though this varies by individual. Anti-inflammatory diets rich in omega-3 fatty acids may be beneficial for overall health.
How quickly do biologic medications work for AOSD?
Response to biologic medications can vary, but many patients notice improvement within days to weeks of starting treatment. Anakinra, in particular, often shows rapid effects on fever and rash, sometimes within 24-48 hours, while joint symptoms may take longer to improve.
Support and resources
- National Organization for Rare Disorders (NORD): rarediseases.org
- Orphanet (European rare disease database): orpha.net
- EURORDIS (European Organisation for Rare Diseases): eurordis.org
- Still’s Disease Research Foundation: International patient support organization
- American College of Rheumatology: rheumatology.org
- Autoinflammatory Alliance: autoinflammatory.org
Related conditions
- Systemic juvenile idiopathic arthritis
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Macrophage activation syndrome
Cite this page
GMJ News Desk. “Adult-onset Still disease.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/adult-onset-still-disease/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?